Glycotest CEO discusses University of Georgia partnership for early liver cancer detection

Proactive - Interviews for investors

Charles Swindell, the CEO of Glycotest, a EMV Capital portfolio company, talked with Proactive's Stephen Gunnion about the company’s progress in liver disease diagnostics, specifically its new partnership with the University of Georgia’s Complex Carbohydrate Research Center (CCRC). Swindell highlighted Glycotest’s focus on detecting early-stage liver cancer using their HCC Panel blood test, which aims to address current limitations in liver cancer diagnostics that often miss early-stage cases. "Our flagship test is the HCC Panel for curable early-stage liver cancer," Swindell noted, explaining how the test could detect cases missed by standard tests. Swindell emphasised the partnership with the University of Georgia CCRC as essential for finalising the commercial platform, which will use the expertise of CCRC in carbohydrate-derived biomarkers for liver disease. With 3.1 million potential test candidates in the US alone and an additional 380 million globally, the market opportunity is vast. "We believe that we are well differentiated from competitors," he added, pointing to the unique biomarkers Glycotest employs. To hear more about Glycotest’s plans for commercialization and how its technology could impact liver disease diagnosis, watch the full interview. Visit Proactive’s YouTube channel for more updates, and don’t forget to like, subscribe, and turn on notifications for our latest videos. #Glycotest #LiverCancer #LiverDisease #CancerDiagnostics #CharlesSwindell #HCCPanel #ProactiveInvestors #MedicalInnovation #UGAPartnership #BiomarkerResearch #HealthTech #ProactiveInvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews